Cardiac Safety Profile of Type II Kinase Inhibitors: Analysis of Post-marketing Reports from Databases of European Medicine Agency & World Health Organization

Overview

Journal Daru

Specialty Pharmacology

Date 2023 May 23

PMID 37221442

Authors

Atul Khurana

Mandeep Kumar Arora

Harikesh Dubey

Affiliations

Soon will be listed here.

Abstract

Background: Targeted therapy with type II kinase inhibitors (KIs) is one of the preferred choices in cancer treatment. However, type II KI therapy can be associated to serious cardiac risks.

Objectives: This study aimed to assess the occurrence of cardiac events reported with type II KIs in Eudravigilance (EV) and VigiAccess databases.

Methods: To evaluate reporting frequency of individual case safety reports (ICSRs) related to cardiac events, we referred EV and VigiAccess databases. The data was retrieved for the period from date of marketing authorization of respective type II KI till 30 July 2022. Computational analysis was conducted with data from EV and VigiAccess using reporting odds ratio (ROR) along with its 95% confidence interval (CI) under Microsoft excel.

Results: In total, 14429 ICSRs in EV and 11522 ICSRs from VigiAccess were retrieved concerning cardiac events with at least one type II KI as the suspected drug. In both databases, most of the ICSRs were reported for Imatinib, Nilotinib, and Sunitinib, while most reported cardiac events were myocardial infarction/acute myocardial infarction, cardiac failure/congestive heart failure and atrial fibrillation. As per EV, 98.8% ICSRs with cardiac ADRs were assessed as serious and of which, 17.4% ICSRs were associated with fatal outcomes and approximately 47% included patient's recovery as a favorable outcome. Nilotinib (ROR 2.87, 95% CI 3.01-2.74) and Nintedanib (ROR 2.17, 95% CI 2.3-2.04) were associated with a significant increase in reporting frequency of ICSRs related to cardiac events.

Conclusions: Type II KI related cardiac events were serious and associated with unfavorable outcomes. A significant increase in ICSRs reporting frequency was observed with Nilotinib and Nintedanib. These results insist for a consideration of revision of cardiac safety profile of Nilotinib and Nintedanib, specifically for risks of myocardial infarction and atrial fibrillation. Additionally, the need for other ad-hoc studies is indicated.

Citing Articles

Atrial Fibrillation and Cancer-Epidemiology, Mechanisms, and Management.

Davis N, Prasitlumkum N, Tan N J Clin Med. 2025; 13(24.

PMID: 39768676 PMC: 11677472. DOI: 10.3390/jcm13247753.

Neuronal toxicity of monoclonal antibodies (mAbs): an analysis of post-marketing reports from FDA Adverse Event Reporting System (FAERS) safety database.

Kumar N, Kalaiselvan V, Arora M Eur J Clin Pharmacol. 2024; 80(11):1685-1695.

PMID: 39052049 DOI: 10.1007/s00228-024-03727-0.

Assessment of Neurologic Safety Profile of Immune Checkpoint Inhibitors: Evaluation of Adverse Drug Reaction Reports.

Khurana A, Dubey H, Arora M Curr Drug Saf. 2024; 19(3):382-394.

PMID: 38310553 DOI: 10.2174/0115748863273507231116112824.

References

Ma G, Murphy J, Martinez M, Sicklick J . Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomarkers Prev. 2014; 24(1):298-302. PMC: 4294949. DOI: 10.1158/1055-9965.EPI-14-1002. View

Santoro M, Mancuso S, Accurso V, Di Lisi D, Novo G, Siragusa S . Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review. Front Physiol. 2021; 12:675811. PMC: 8287514. DOI: 10.3389/fphys.2021.675811. View

Lyon A, Lopez-Fernandez T, Couch L, Asteggiano R, Aznar M, Bergler-Klein J . 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022; 23(10):e333-e465. DOI: 10.1093/ehjci/jeac106. View

Ruggiero R, Fraenza F, Scavone C, Mauro G, Piscitelli R, Mascolo A . Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database. Front Pharmacol. 2020; 11:830. PMC: 7295943. DOI: 10.3389/fphar.2020.00830. View

Noseda R, Bonaldo G, Motola D, Stathis A, Ceschi A . Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase. Cancers (Basel). 2021; 13(5). PMC: 7961480. DOI: 10.3390/cancers13051131. View

Jin Y, Xu Z, Yan H, He Q, Yang X, Luo P . A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors. Front Pharmacol. 2020; 11:891. PMC: 7303342. DOI: 10.3389/fphar.2020.00891. View

Lee P, Yeoh Y, Low T . A recent update on small-molecule kinase inhibitors for targeted cancer therapy and their therapeutic insights from mass spectrometry-based proteomic analysis. FEBS J. 2022; 290(11):2845-2864. DOI: 10.1111/febs.16442. View

Padala S, Barsouk A, Thandra K, Saginala K, Mohammed A, Vakiti A . Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020; 11(3):79-87. PMC: 7239575. DOI: 10.14740/wjon1279. View

Hou W, Ding M, Li X, Zhou X, Zhu Q, Varela-Ramirez A . Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials. J Cancer Res Clin Oncol. 2021; 147(8):2407-2420. PMC: 8236482. DOI: 10.1007/s00432-021-03521-w. View

10.

Cirmi S, El Abd A, Letinier L, Navarra M, Salvo F . Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS). Cancers (Basel). 2020; 12(4). PMC: 7226142. DOI: 10.3390/cancers12040826. View

11.

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

12.

Mascolo A, Scavone C, Ferrajolo C, Rafaniello C, Danesi R, Del Re M . Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance. Drug Saf. 2021; 44(9):957-971. PMC: 8370948. DOI: 10.1007/s40264-021-01086-8. View

13.

Sturgeon K, Deng L, Bluethmann S, Zhou S, Trifiletti D, Jiang C . A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019; 40(48):3889-3897. PMC: 6925383. DOI: 10.1093/eurheartj/ehz766. View

14.

Lamore S, Kohnken R, Peters M, Kolaja K . Cardiovascular Toxicity Induced by Kinase Inhibitors: Mechanisms and Preclinical Approaches. Chem Res Toxicol. 2019; 33(1):125-136. DOI: 10.1021/acs.chemrestox.9b00387. View

15.

Aghel N, Delgado D, Lipton J . Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc Health Risk Manag. 2017; 13:293-303. PMC: 5552150. DOI: 10.2147/VHRM.S108874. View

16.

Ning L, Hu C, Lu P, Que Y, Zhu X, Li D . Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study. Exp Hematol Oncol. 2020; 9(1):29. PMC: 7607878. DOI: 10.1186/s40164-020-00185-z. View

17.

Grela-Wojewoda A, Pacholczak-Madej R, Adamczyk A, Korman M, Puskulluoglu M . Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer. Int J Mol Sci. 2022; 23(5). PMC: 8910876. DOI: 10.3390/ijms23052815. View

18.

Vallerio P, Orenti A, Tosi F, Maistrello M, Palazzini M, Cingarlini S . Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management. ESMO Open. 2021; 7(1):100338. PMC: 8685997. DOI: 10.1016/j.esmoop.2021.100338. View

19.

Raschi E, Mazzarella A, Antonazzo I, Bendinelli N, Forcesi E, Tuccori M . Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. Target Oncol. 2019; 14(2):205-221. DOI: 10.1007/s11523-019-00632-w. View

20.

Noth I, Wijsenbeek M, Kolb M, Bonella F, Moros L, Wachtlin D . Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials. Eur Respir J. 2019; 54(3). PMC: 6766682. DOI: 10.1183/13993003.01797-2018. View